Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430574 | 0.97 | CDK2 (0.49) | CDK2KCNH2AURKAAURKBCDK1 | |
| SCHEMBL4435674 | 0.96 | CDK2 (0.49) | CDK2KCNH2AURKAAURKBCDK1 | |
| SCHEMBL4433038 | 0.96 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2MAPK8 | |
| SCHEMBL4434460 | 0.95 | CDK2 (0.48) | CDK2KCNH2CDK1JAK2MAPK8 | |
| SCHEMBL3942209 | 0.93 | CDK2 (0.48) | CDK2KCNH2CDK1CDK4 | |
| SCHEMBL4436650 | 0.92 | CDK2 (0.46) | CDK2KCNH2AURKAAURKBCDK1 | |
| SCHEMBL14092821 | 0.92 | CDK2 (0.46) | CDK2KCNH2CDK1JAK2JAK1 | |
| SCHEMBL4436531 | 0.92 | CDK2 (0.47) | CDK2KCNH2CDK1JAK2JAK1 | |
| SCHEMBL4428626 | 0.92 | CDK2 (0.46) | CDK2KCNH2AURKAAURKBCDK1 | |
| SCHEMBL4432737 | 0.91 | CDK2 (0.45) | CDK2KCNH2CDK1CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| US-20230115252-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016207366-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | CDK2 328/4885KCNH2 3601/4885AURKA 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.